Nonpharmacological treatment options for Alzheimer’s disease: from animal testing to  clinical studies

Türkez, Hasan; Arslan, Mustafa; Stefano, Antonio Di; Cacciatore, Ivana; Mardinoğlu, Adil

doi:10.3906/zoo-1911-32

Cited by 6 publications

(1 citation statement)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Al accumulation might be associated with the etiology of various neurological disorders, such as dementia, senile dementia, and AD [ 25 , 26 ]. In patients with AD, the two lesions-senile plaques and neurofibrillary tangles are found in aluminum, suggesting a causal association between Al exposure and AD [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

In Vitro and In Vivo Neuroprotective Effects of Sarcosine

Tanas

Tozlu

Gezmiş

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by behavioral and psychological symptoms in addition to cognitive impairment and loss of memory. The exact pathogenesis and genetic background of AD are unclear and there remains no effective treatment option. Sarcosine, an n-methyl derivative of glycine, showed a promising therapeutic strategy for some cognitive disorders. To our knowledge, the impacts of sarcosine supplementation against AD have not yet been elucidated. Therefore, we aimed to determine the neuroprotective potential of sarcosine in in vitro and in vivo AD model. In vitro studies have demonstrated that sarcosine increased the percentage of viable cells against aluminum induced neurotoxicity. In AlCl3-induced rat model of AD, the level of antioxidant capacity was significantly decreased and expression levels of APP, BACE1, TNF-α, APH1A, and PSENEN genes were elevated compared to the control group. Additionally, histopathological examinations of the hippocampus of AlCl3-induced rat brains showed the presence of neurofibrillary tangles (NFTs). However, the administration of sarcosine produced marked improvement and protection of AD-associated pathologies induced by AlCl3 in experimental rats. Therefore, this investigation may contribute to design novel therapeutic strategies using sarcosine for the management of AD pathologies.

show abstract

Section: Introductionmentioning

confidence: 99%

In Vitro and In Vivo Neuroprotective Effects of Sarcosine

Tanas

Tozlu

Gezmiş

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

Borax attenuates oxidative stress, inflammation, and apoptosis by modulating Nrf2/ROS balance in acrylamide-induced neurotoxicity in rainbow trout

Turkez,

Alak,

Ozgeris

et al. 2024

Drug and Chemical Toxicology

View full text Add to dashboard Cite

Machine learning analysis reveals biomarkers for the detection of neurodegenerative diseases

Lam

Arif

Song

et al. 2022

Preprint

View full text Add to dashboard Cite

It is critical to identify biomarkers for neurodegenerative diseases (NDDs) to advance disease diagnosis and accelerate drug discovery for effective treatment of patients. In this work, we retrieved genotyping and clinical data from 1223 UK Biobank participants to identify genetic and clinical biomarkers for NDDs, including Alzheimer’s disease (AD), Parkinson’s disease (PD), motor neuron disease (MND), and myasthenia gravis (MG). Using a machine learning modelling approach and Monte Carlo randomisation, we identified 16 informative clinical variables for predicting AD, PD, MND, and MG. In a multinomial model, these clinical variables could correctly predict the diagnosis of one of the four diseases with an accuracy of 88.3%. In addition to clinical biomarkers, we also explored genetic biomarkers. In a genome-wide association study of AD, PD, MND, and MG patients, we identified single nucleotide polymorphisms (SNPs) implicated in several craniofacial disorders such as apnoea and branchiootic syndrome. We found evidence for shared genetic risk loci across NDDs, including SNPs in cancer-related genes and SNPs known to be associated with non-brain cancers such as Wilms tumour, leukaemia, and pancreatic cancer. Our analysis supports current knowledge regarding the ageing-related degeneration/cancer shift.Significance statementThis study highlights the potential for hypothesis-free mathematical modelling of easily measured clinical variables to identify diagnostic biomarkers for neurodegenerative diseases (NDDs). Prior to this study, the focus in NDD research has surrounded toxic species such as amyloid beta and α-synuclein, but this approach has not enjoyed success at clinical trial. Here, we studied Alzheimer’s disease, Parkinson’s disease, motor neuron disease, and myasthenia gravis by constructing and inspecting a multinomial based on demographics and blood and urine biochemistry. Cognitive measures were important for the predictive power of the model. Model weights correctly indicated multiple trends reported in the literature. Separately, genome-wide association indicated a shared risk profile between NDD and cancer, which has also been reported in the literature.

show abstract

Nonpharmacological treatment options for Alzheimer’s disease: from animal testing to clinical studies

Cited by 6 publications

References 60 publications

In Vitro and In Vivo Neuroprotective Effects of Sarcosine

In Vitro and In Vivo Neuroprotective Effects of Sarcosine

Borax attenuates oxidative stress, inflammation, and apoptosis by modulating Nrf2/ROS balance in acrylamide-induced neurotoxicity in rainbow trout

Machine learning analysis reveals biomarkers for the detection of neurodegenerative diseases

Contact Info

Product

Resources

About